Loading…
← CockpitCompetitor Analysis › 688221.SS Frontier Biotechnologies Inc. Class AOpen in the cockpit ↗

Frontier Biotechnologies Inc. Class A688221.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology
Momentum laggard 5
Mkt cap
$658M
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$15.5M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-15.2 pp
WACC 11.3%
Hurdle
+19 pp
Req g minus delivered
Next earnings
128 days
26 Mar 2027
Close · CNYCN¥11.94
1D-2.0%
1W-14.0%
1M-15.9%
3M-44.5%
6M-47.7%
YTD-33.9%
1Y-22.1%
ATR %6.0%
52w lowhigh60.2% off high

What Frontier Biotechnologies does

Employees: 314

Frontier Biotechnologies at a glance

Size Frontier Biotechnologies (688221.SS) is a China Health Care company (Biotechnology) with a market value of $658M, the 3039th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.94 on 18 Nov 2026.

Performance Over six months the shares fell 47.7%, against -14.7% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 18 in its peer set.

Growth Revenue grew 153.4% over the last twelve months (peer median +18.1%); the operating margin is -19.6% (peer median -105.4%).

Valuation It trades at 11.4× enterprise value to sales against a peer median of 6.9× (7th most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 40% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 15.2 points below its cost of capital (11.3% WACC).

Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).

Relative performance

507510012521 May 202621 Aug 202618 Nov 2026Peer median 86688221.SS 54
Six months, rebased to 100: Frontier Biotechnologies against the median of its 20 peers (local-currency closes).

Frontier Biotechnologies financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥358MCN¥123MCN¥129MCN¥114MCN¥84.7M
Revenue growth—-5%+13%+35%—
Gross profitCN¥293MCN¥30.3MCN¥27.0MCN¥11.3M-CN¥9.02M
EBITDAn/a-CN¥237M-CN¥236M-CN¥297M-CN¥346M
Net income-CN¥35.8M-CN¥268M-CN¥201M-CN¥329M-CN¥357M
Free cash flowCN¥52.7M-CN¥244M-CN¥175M-CN¥379M-CN¥409M
Capital expenditureCN¥11.1MCN¥29.9MCN¥18.6MCN¥129MCN¥140M
Total debtCN¥375MCN¥406MCN¥407MCN¥380MCN¥279M

Quarterly statements and history in the cockpit →

Frontier Biotechnologies competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+500%+1,000%0%+50%68819799667729KURAGERN301520JANXATTOSRZN688221.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Frontier Biotechnologies is the large dot.

Fundamentals: revenue growth against valuation

0%+2,000%+4,000%0×50×100×6881979966KURA301520PRMESRZN6886399637688221.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Frontier Biotechnologies is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%301520603387301333002038688221.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Frontier Biotechnologies is the large dot.

Frontier Biotechnologies competitors and peer comparison

How Frontier Biotechnologies compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Frontier Biotechnologies against its 20 peers (data as of 18 Nov 2026)
Measure688221.SSPeer medianRank in peer set
1-month return-15.9%-7.0%6th lowest of 21
6-month return-47.7%-14.7%lowest of 18
Distance from 52-week high-60.2%-44.8%3rd lowest of 21
Revenue growth (TTM)+153.4%+18.1%5th highest of 16
Operating margin-19.6%-105.4%7th highest of 17
EV / Sales11.4×6.9×7th most expensive of 16
Growth the price implies (Req g, 7 yrs)40.3%4.2%2nd most demanding of 5
Growth delivered (Del g)+21.5%+5.3%highest of 5
Hurdle (Req g minus delivered)+18.8 pp+1.4 pp2nd most demanding of 5
ROIC minus cost of capital-15.2 pp-14.9 pp6th lowest of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Frontier Biotechnologies 688221.SSChina$658M-48%+153%-20%11.4×40.3%+21.5%
Shouyao Holdings Beijing 688197.SSChina$653M-26%+4,564%-92%38.1×n/an/a
Alphamab Oncology 9966.HKHong Kong$666M-38%-32%-38%6.7×n/an/a
Steminent Biotherapeutics 7729.TWOTaiwan$668M+292%n/an/an/an/an/a
Kura Oncology KURAUnited States$674M-29%-24%-394%2.6×n/an/a
Geron GERNUnited States$638M-21%+19%-8%2.8×n/an/a
Anhui Wanbang Pharmaceutical Technology 301520.SZChina$684M+74%-15%-8%14.7×44.8%+14.7%
Shenzhen Weiguang Biological Products 002880.SZChina$633M-27%0%18%4.4×n/an/a
Janux Therapeutics JANXUnited States$631M-28%+133%-599%n/an/an/a
Getein Biotech 603387.SSChina$625M-13%+8%21%2.6×-8.9%-1.3%
Prime Medicine PRMEUnited States$695M+35%+18%-2,584%105.4×n/an/a
Solid Biosciences SLDBUnited States$709M-2%n/an/an/an/an/a
Attovia Therapeutics ATTOUnited States$710M+1,325%n/a-5,945%220.7×n/an/a
Shaanxi Micot Pharmaceutical Technology 2335.HKHong Kong$715Mn/an/an/an/an/an/a
Design Therapeutics DSGNUnited States$606M-15%n/an/an/an/an/a
Surrozen SRZNUnited States$605M+17%+192%-485%48.5×n/an/a
Anhui Huaheng Biotechnology 688639.SSChina$605M-45%+7%3%1.9×n/an/a
R&G PharmaStudies 301333.SZChina$722M-11%+21%11%3.4×17.3%+11.8%
Apnimed APMDUnited States$726Mn/a+380%-140%10.8×n/an/a
Alebund Pharmaceuticals (Jiangsu) 9637.HKHong Kong$595Mn/a+674%-495%26.8×n/an/a
Beijing SL Pharmaceutical 002038.SZChina$736M-20%-4%-119%6.9×-13.5%-10.9%

Questions

Which companies are Frontier Biotechnologies's closest peers?
The cockpit's peer set: Shouyao Holdings Beijing (688197.SS), Alphamab Oncology (9966.HK), Steminent Biotherapeutics (7729.TWO), Kura Oncology (KURA), Geron (GERN), Anhui Wanbang Pharmaceutical Technology (301520.SZ), Shenzhen Weiguang Biological Products (002880.SZ), Janux Therapeutics (JANX).
Is Frontier Biotechnologies expensive compared with its peers?
On ev / sales it trades at 11.4× against a peer median of 6.9×, 7th most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 40% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Frontier Biotechnologies stock performed?
Over six months to 18 Nov 2026 the shares returned -47.7% against -14.7% for the median peer; over one year -22.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.